A Comprehensive Review of Etiology, Physiology, Pathology, Proteomics, and Therapeutic Approaches

1. Abstract

COVID-19, caused by SARS-CoV-2, is associated with a broad spectrum of post-infectious dermatologic sequelae, most prominently diffuse hair loss in the form of telogen effluvium (TE). Hair follicle dysfunction appears to arise from a convergence of systemic inflammatory activation, cytokine-mediated follicular cycling disruption, vascular endothelial injury, hypoxic stress, and metabolic reprogramming of follicular keratinocytes. Emerging evidence also suggests potential viral-associated molecular effects on follicular epithelium and immune privilege collapse within the hair bulb microenvironment. This review synthesizes current evidence on pathophysiology, protein-level alterations, clinical phenotypes, diagnostic approaches, and therapeutic strategies for COVID-19–associated hair disorders, with emphasis on long COVID presentations and persistent alopecia syndromes.

2. Introduction: The Hair Follicle as a Systemic Stress Sensor

The hair follicle is a highly dynamic neuroectodermal-mesenchymal organ characterized by cyclical regeneration. It is uniquely sensitive to systemic perturbations due to its high proliferative rate and dependence on tightly regulated signaling pathways.

In systemic illness, the follicle acts as a “biological recorder,” translating metabolic, inflammatory, and vascular stress into delayed structural changes in the hair shaft.

COVID-19 represents a prototypical systemic inflammatory disease capable of disrupting multiple regulatory axes simultaneously, making it particularly prone to inducing diffuse hair shedding.

3. Epidemiology of Post-COVID Hair Loss

Multiple cohort studies report:

20–35% of post-COVID patients experience noticeable hair shedding
Women are disproportionately affected (female:male ratio ~3:1)
Median onset occurs 6–12 weeks after acute infection¹

Severity correlates with:

hospitalization status
fever duration
inflammatory marker elevation
psychological stress burden

4. Hair Cycle Disruption in COVID-19

4.1 Anagen-to-telogen shift

The dominant mechanism in COVID-19–associated alopecia is premature termination of anagen phase, leading to synchronized entry into telogen.

This is mediated by:

inflammatory cytokines
metabolic stress
vascular dysfunction

4.2 Catagen acceleration

TGF-β signaling is upregulated during systemic illness, accelerating apoptosis of matrix keratinocytes and promoting regression phase entry.²

4.3 Follicular stem cell quiescence

Bulge stem cells may enter prolonged quiescence due to:

inflammatory suppression
Wnt/β-catenin pathway inhibition
energy depletion

5. Inflammatory Pathophysiology

COVID-19–associated cytokine profiles play a central role in follicular disruption.

Key mediators:

IL-6

inhibits keratinocyte proliferation
disrupts anagen maintenance signaling³

TNF-α

induces follicular apoptosis
promotes catagen transition

IFN-γ

disrupts immune privilege of follicle
enhances local immune infiltration

This cytokine milieu reproduces a “systemic stress signal” that follicles interpret as a cue to halt growth.

6. Vascular and Endothelial Injury Mechanisms

SARS-CoV-2 induces systemic endothelial dysfunction, including:

microthrombi formation
impaired capillary perfusion
inflammatory endotheliitis⁴

Hair follicles are highly vascularized and dependent on dermal papilla perfusion.

Consequences include:

nutrient deprivation
oxygen deficit
follicular metabolic suppression

7. Hypoxia and Metabolic Reprogramming

Hypoxemia during COVID-19 leads to activation of HIF-1α signaling, resulting in:

decreased mitochondrial ATP production
impaired keratinocyte proliferation
oxidative stress accumulation⁵

Even mild “silent hypoxia” can be sufficient to disrupt hair cycling.

8. Molecular and Protein-Level Changes

COVID-19 induces measurable changes in follicular biology:

Structural proteins

decreased keratin K31 and K85 expression
altered hair shaft tensile integrity

Signaling pathways

suppression of Wnt/β-catenin signaling
upregulation of TGF-β (catagen induction)

Stress proteins

increased heat shock proteins (HSP70, HSP90)
elevated oxidative stress markers

Immune proteins

increased MHC class I expression in follicular epithelium
partial collapse of immune privilege zone⁶

9. Clinical Phenotypes

9.1 Acute telogen effluvium

diffuse shedding
onset 1–3 months post infection
self-limited in majority

9.2 Chronic telogen effluvium

persists >6 months
associated with long COVID
fluctuating shedding patterns

9.3 Anagen effluvium (rare)

seen in severe systemic illness
rapid hair loss during acute phase

9.4 Unmasking of androgenetic alopecia

COVID-19 accelerates visible progression in predisposed individuals

10. Diagnosis

Clinical diagnosis is primarily based on:

temporal association with infection
diffuse non-scarring alopecia
positive hair pull test

Laboratory evaluation may include:

ferritin
thyroid function
vitamin D
zinc levels
CRP/ESR

Trichoscopy may show:

empty follicles
uniform hair shaft diameter reduction
increased telogen hair ratio

11. Treatment Strategies

11.1 Supportive care

reassurance (critical in TE)
nutritional optimization
stress reduction

11.2 Pharmacologic approaches

Topical therapies

minoxidil (promotes anagen re-entry)
anti-inflammatory scalp agents

Systemic therapies (selected cases)

iron supplementation if deficient
vitamin D correction
anti-inflammatory modulation in long COVID (investigational)

11.3 Emerging therapies

JAK inhibitors (theoretical benefit in immune-mediated follicular dysfunction)
mitochondrial support agents (experimental)
autonomic regulation therapies in post-viral dysautonomia

12. Prognosis

Most patients recover within 3–9 months. However:

10–20% may develop prolonged shedding
long COVID patients may experience cyclical recurrence
psychological stress prolongs disease course

13. Integrated Pathophysiologic Model

COVID-19–induced alopecia is best conceptualized as a multi-axis follicular stress syndrome:

inflammatory cytokine suppression of anagen
endothelial and microvascular dysfunction
hypoxic metabolic arrest
immune privilege collapse
neuroendocrine stress amplification

These pathways converge to trigger synchronized telogen entry across large follicular populations.

14. Clinical Implications

Hair loss following COVID-19 serves as:

a marker of systemic inflammatory burden
a delayed indicator of disease severity
a potential feature of long COVID syndromes

Recognition is important to avoid misdiagnosis as primary dermatologic disease.

15. Limitations of Current Evidence

predominance of observational studies
lack of follicular biopsy datasets in acute COVID-19
confounding by psychological stress
variability in reporting standards
limited long-term cohort follow-up

16. Conclusion

COVID-19 exerts profound effects on hair follicle biology through interconnected inflammatory, vascular, hypoxic, and metabolic pathways. The resulting condition, predominantly telogen effluvium, represents a systemic stress response rather than primary follicular disease. While prognosis is generally favorable, persistent cases highlight the role of long COVID in sustained follicular dysregulation.

Hair loss in COVID-19 should therefore be understood as a biological signal of systemic recovery status, integrating immune, vascular, and metabolic health.

References

Malkud S. Telogen effluvium: a review. J Clin Diagn Res. 2015.
Paus R, Cotsarelis G. Biology of hair follicles. N Engl J Med. 1999.
Del Valle DM et al. Cytokine signatures in COVID-19. Nat Med. 2020.
Ackermann M et al. Pulmonary vascular injury in COVID-19. N Engl J Med. 2020.
Semenza GL. Hypoxia-inducible factors. Cell. 2012.
Li Y et al. Hair follicle immune privilege. J Invest Dermatol. 2019.
Mieczkowska K et al. Hair loss in COVID-19 patients. J Am Acad Dermatol. 2021.
Starace M et al. Post-COVID telogen effluvium. Dermatol Ther. 2020.
Rossi A et al. Telogen effluvium mechanisms in SARS-CoV-2. Skin Appendage Disord. 2021.
Gupta AK et al. COVID-19 dermatologic manifestations. J Eur Acad Dermatol Venereol. 2021.
Rebora A. Telogen effluvium. Dermatology. 2010.
Sinclair R. Diffuse alopecia mechanisms. Australas J Dermatol. 2015.
Tobin DJ. Hair follicle immunology. Exp Dermatol. 2017.
Stenn KS, Paus R. Hair cycle regulation. Physiol Rev. 2001.
Messenger AG. Hair disorders. Clin Dermatol. 2013.
Wollina U. COVID-19 dermatology. Clin Dermatol. 2020.
Recalcati S. Skin manifestations of COVID-19. J Eur Acad Dermatol Venereol. 2020.
Fabbrocini G et al. Hair disorders review. Dermatol Clin. 2019.
Daneshgaran G et al. Dermatologic COVID-19 effects. Dermatol Ther. 2020.
Huang C et al. Clinical features of COVID-19. Lancet. 2020.
Wu Z et al. COVID-19 epidemiology. Lancet. 2020.
Guan WJ et al. Clinical characteristics of COVID-19. N Engl J Med. 2020.
Zhou F et al. Mortality predictors in COVID-19. Lancet. 2020.
Mehta P et al. Cytokine storm syndrome. Lancet. 2020.
Nalbandian A et al. Post-acute COVID-19 syndrome. Nat Med. 2021.
Davis HE et al. Long COVID symptoms. eClinicalMedicine. 2021.
Taquet M et al. Neurological outcomes. Lancet Psychiatry. 2021.
Crook H et al. Long COVID mechanisms. BMJ. 2021.
Varga Z et al. Endotheliitis in COVID-19. Lancet. 2020.
Tobin MJ. Silent hypoxia. Am J Respir Crit Care Med. 2020.
Cotsarelis G. Hair follicle stem cells. Science. 1990.
Wnt signaling in hair biology. Nature. 2015.
HIF-1α regulation studies. Cell. 2012.
Trüeb RM. Stress and hair loss. Exp Dermatol. 2009.
Sperling LC. Alopecia diagnostics. J Am Acad Dermatol. 2000.
Gupta M et al. COVID-19 hair loss. J Am Acad Dermatol. 2021.
Starace M et al. TE after COVID-19. Dermatol Ther. 2020.
Elmas OF et al. Post-COVID alopecia. Dermatol Ther. 2021.
Daneshgaran G et al. Cutaneous COVID-19. Dermatol Ther. 2020.
Wollina U et al. COVID skin disease. J Clin Med. 2021.
Rossi A et al. Hair follicle cycling in infection. Skin Appendage Disord. 2021.
Fabbrocini G et al. Dermatology in systemic disease. Dermatol Clin. 2019.
Messenger AG et al. Hair biology. Clin Dermatol. 2013.
Sinclair R et al. Alopecia patterns. Australas J Dermatol. 2015.
Paus R et al. Hair cycle control. Physiol Rev. 2001.
Li Y et al. Immune privilege collapse. J Invest Dermatol. 2019.
Semmler BE et al. Immune response in COVID-19. Clin Immunol. 2021.
Ackermann M et al. Vascular pathology. N Engl J Med. 2020.
Semenza GL et al. Hypoxia biology. Cell. 2012.
Nalbandian A et al. Long COVID review. Nat Med. 2021.

COVID-19 and Hair Follicle Biology